Back to Search Start Over

Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair

Authors :
Valerie de Haas
Eveline S. J. M. de Bont
Steven M. Kornblau
Victor Guryev
Kim R. Kampen
Hasan Mahmud
Tiny G. J. Meeuwsen-de Boer
Maikel M Peppelenbosch
Frank J. G. Scherpen
Arja ter Elst
Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Gastroenterology & Hepatology
Source :
Oncotarget, 10(45), 4679-4690. Impact Journals LLC, Scopus-Elsevier, Oncotarget
Publication Year :
2019
Publisher :
Impact Journals, LLC, 2019.

Abstract

The majority of acute myeloid leukemia (AML) patients suffer from relapse and the exact etiology of AML remains unclear. The aim of this study was to gain comprehensive insights into the activity of signaling pathways in AML. In this study, using a high-throughput PepChip™ Kinomics microarray system, pediatric AML samples were analyzed to gain insights of active signal transduction pathway. Unsupervised hierarchical cluster analysis separated the AML blast profiles into two clusters. These two clusters were independent of patient characteristics, whereas the cumulative incidence of relapse (CIR) was significantly higher in the patients belonging to cluster-2. In addition, cluster-2 samples showed to be significantly less sensitive to various chemotherapeutic drugs. The activated peptides in cluster-1 and cluster-2 reflected the activity of cell cycle regulation, cell proliferation, cell differentiation, apoptosis, PI3K/AKT, MAPK, metabolism regulation, transcription factors and GPCRs signaling pathways. The difference between two clusters might be explained by the higher cell cycle arrest response in cluster-1 patients and higher DNA repair mechanism in cluster-2 patients. In conclusion, our study identifies different signaling profiles in pediatric AML in relation with CIR involving DNA damage response and repair.

Details

ISSN :
19492553
Volume :
10
Database :
OpenAIRE
Journal :
Oncotarget
Accession number :
edsair.doi.dedup.....4940e64f31fed14b1be315ceb45c94b7
Full Text :
https://doi.org/10.18632/oncotarget.27086